BeiGene
BGNE
#971
Rank
โ‚น1.699 T
Marketcap
โ‚น15,204
Share price
0.53%
Change (1 day)
4.05%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Revenue for BeiGene (BGNE)

Revenue in 2024 (TTM): โ‚น276.79 Billion

According to BeiGene 's latest financial reports the company's current revenue (TTM ) is โ‚น282.30 Billion. In 2023 the company made a revenue of โ‚น204.69 Billion an increase over the revenue in the year 2022 that were of โ‚น117.16 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BeiGene from 2015 to 2024

201620192022โ‚น50Bโ‚น100Bโ‚น150Bโ‚น200Bโ‚น250Bโ‚น300B0companiesmarketcap.com

Annual revenue

Year Revenue Change
2024 (TTM) โ‚น276.79 B35.23%
2023 โ‚น204.69 B74.7%
2022 โ‚น117.16 B33.83%
2021 โ‚น87.55 B287.58%
2020 โ‚น22.58 B-26.02%
2019 โ‚น30.53 B120.32%
2018 โ‚น13.86 B-8.94%
2017 โ‚น15.22 B20833.65%
2016 โ‚น72.71 M-87.59%
2015 โ‚น0.58 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚น19.23 M-99.99%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น60.55 B-78.55%๐Ÿ‡บ๐Ÿ‡ธ USA